Bruno Sangro

48.5k citations
416 papers · 26.0k indexed · 23 hit papers · h-index 77

Impact in

  • Hepatology top 0.01%
    • Hepatocellular Carcinoma Treatment and Prognosis
    • Liver Disease and Transplantation
    • Hepatitis C virus research
  • Oncology top 0.1%
    • Cancer Immunotherapy and Biomarkers

Papers in

    • Hepatocellular Carcinoma Treatment and Prognosis 220
    • Liver Disease and Transplantation 48
    • Cancer Immunotherapy and Biomarkers 67
    • Colorectal Cancer Treatments and Studies 30
    • Pancreatic and Hepatic Oncology Research 28

Bruno Sangro

394 papers receiving 25.6k citations

Hit Papers

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. 2024 · 75 citations
75201020262015202050010001.5k2.0k

Peers

Bruno Sangro
Comparison fields: 5 of 145
  • Hepatology 16.2k
  • Oncology 7.6k
  • Epidemiology 8.4k
  • Cancer Research 3.5k
  • Pathology and Forensic Medicine 2.9k
Replace Vincenzo Mazzaferro with:
Vincenzo Mazzaferro Italy
Myron Schwartz United States
Philip J. Johnson United Kingdom
Sheung Tat Fan Hong Kong
Laura Kulik United States
Andrew X. Zhu United States
Peter Schirmacher Germany
Norihiro Kokudo Japan
Tadatoshi Takayama Japan
Yasuni Nakanuma Japan
Bruno Sangro relative to Vincenzo Mazzaferro Italy Vincenzo Mazzaferro's profile →
Citations per field
00.5×1.5×
Vincenzo Mazzaferro · 1×
Citations per year

Countries citing papers authored by Bruno Sangro

Since Specialization
Citations

This map shows the geographic impact of Bruno Sangro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruno Sangro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruno Sangro more than expected).

Fields of papers citing papers by Bruno Sangro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruno Sangro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruno Sangro. The network helps show where Bruno Sangro may publish in the future.

Co-authors

The 25 scholars most cited alongside Bruno Sangro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bruno Sangro Line = papers co-authored together Bruno Sangro links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20240
2 20241
3 20241
4 20244
5
Combination immunotherapy for hepatocellular carcinoma
Hit paper breakdown →
2023179
6 20238
7 20230
8 202275
9 202226
10 20227
11 202132
12 202111
13 202012
14 201928
15 2017190
16 2014204
17 201381
18 2010151
19 200946
20 20055

About Bruno Sangro

Bruno Sangro is a scholar working on Hepatology, Oncology, Epidemiology, Transplantation and Pulmonary and Respiratory Medicine, having authored 416 papers that have together received 26.0k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (220 papers), Liver Disease Diagnosis and Treatment (83 papers), Cancer Immunotherapy and Biomarkers (67 papers), Liver Disease and Transplantation (48 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (39 papers), Hepatitis B Virus Studies (38 papers), Colorectal Cancer Treatments and Studies (30 papers) and Pancreatic and Hepatic Oncology Research (28 papers). The work is most often cited by research in Hepatology (16.2k citations), Oncology (7.6k citations), Epidemiology (8.4k citations), Cancer Research (3.5k citations) and Pathology and Forensic Medicine (2.9k citations). Bruno Sangro has collaborated with scholars based in Spain, United States and Germany. Frequent co-authors include Jesús Prìeto, Ignacio Melero, Mercedes Iñarrairaegui, Josep M. Llovet, Vincenzo Mazzaferro, Riad Salem, Peter R. Galle, Pablo Sarobe, José Ignacio Bilbao and Jordi Bruix. Their work appears in journals such as Journal of Hepatology, Journal of Clinical Oncology, Annals of Oncology, Hepatology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026